Dermatologic Therapy最新文献

{"title":"The Efficacy and Safety of Ablative Fractional CO2 Laser Combined With Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial","authors":"Xu Zhao,&nbsp;Lin Peng,&nbsp;Fanjun Xu,&nbsp;Yu Han,&nbsp;Lutong Li,&nbsp;Lili Zhang,&nbsp;Liangliang Shen,&nbsp;Shuo Lou,&nbsp;Miao Jiang","doi":"10.1155/dth/6654837","DOIUrl":"https://doi.org/10.1155/dth/6654837","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Minoxidil is a primary treatment for male androgenetic alopecia (AGA), but its slow onset and limited effectiveness, especially in restoring the frontal hairline in basic M-type AGA, often result in poor adherence. We investigated whether combining minoxidil with ablative fractional CO₂ laser, which enhances transdermal absorption and the follicular environment, could improve outcomes. This study assesses the efficacy and safety of this combination therapy in overcoming these challenges.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 178 male patients with basic M-type AGA were randomized into two treatment arms: the combination therapy arm (application of 5% minoxidil twice daily; monthly ablative fractional CO₂ laser treatment for 24 weeks) and the monotherapy arm (application of 5% minoxidil twice daily for 24 weeks). Follow-ups were conducted at baseline, 12 weeks, and 24 weeks after treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Out of 178 patients randomized (89 in each arm), 156 completed 24 weeks (combination: 83; monotherapy: 73). The combination therapy significantly improved terminal hair density, diameter, investigator assessments, and patient satisfaction compared to monotherapy (all <i>p</i> &lt; 0.001). Trichoscopic analysis showed better hair density diversity, perifollicular pigmentation, honeycomb pattern, and double hair units in the combination arm (all <i>p</i> &lt; 0.025). No serious treatment-related adverse events occurred in either group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The combination of ablative fractional CO₂ laser and topical minoxidil is more effective than topical minoxidil monotherapy in promoting frontal hairline regrowth, with faster response time and comparable safety profiles.</p>\u0000 \u0000 <p><b>Trial Registration:</b> Chinese Registry of Clinical Trials: ChiCTR2300070840.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6654837","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Therapy for Keloid Following Toe Syndactyly Division in Children: 1470 nm Laser and Glucocorticoid Injection (1470 LAGI)","authors":"Xinxian Meng,&nbsp;Chunxiao Cui,&nbsp;Ke Wen,&nbsp;Xueqian Wang,&nbsp;Chengyao Han,&nbsp;Yuhao Sun,&nbsp;Jingshu Wu,&nbsp;Peiru Min,&nbsp;Fabio Nicoli,&nbsp;Hua Li,&nbsp;Yixin Zhang,&nbsp;Ke Li","doi":"10.1155/dth/6625620","DOIUrl":"https://doi.org/10.1155/dth/6625620","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Keloid development following toe syndactyly division is a rare but troublesome condition, which can impose both esthetic and functional burden. Currently, there is no effective treatment for this condition. The present study proposed a new treatment for keloid after syndactyly division by 1470 nm laser and glucocorticoid injection (1470 LAGI). This study aimed to evaluate the efficacy of this treatment modality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective study was conducted on 12 patients with 36 keloid cases, who underwent treatment with 1470 LAGI. VSS scores were applied for keloid evaluation (pigmentation, vascularity, pliability, and height). VAS was applied for assessing pain and itching, and the recovery rate was recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This study showed that the 1470 LAGI can improve the pathological status of keloids from toe syndactyly division (<i>p</i> &lt; 0.001), with a recovery rate of 30.56%. Itching and pain also significantly improved (<i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In terms of vascularity, pigmentation, pliability, and height, 1470 LAGI led to keloid regression after toe syndactyly division, with a recovery rate of 30.56%. Besides, the combined treatment significantly decreased the episodes of itching and pain, thereby improving the quality of life. Therefore, it is an effective minimally invasive treatment for keloid following toe syndactyly division in children.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6625620","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics, Treatment, and Prognosis of Hydroxychloroquine-Induced Acute Generalized Exanthematous Pustulosis","authors":"Fei Lu,&nbsp;Ying Song,&nbsp;Chunjiang Wang","doi":"10.1155/dth/5392334","DOIUrl":"https://doi.org/10.1155/dth/5392334","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The clinical characteristics of hydroxychloroquine (HCQ)-induced acute generalized exanthematous pustulosis (AGEP) remain inadequately defined. This research sought to define the incidence and clinical course of AGEP following HCQ administration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a retrospective analysis of clinical cases of HCQ-induced AGEP by systematically reviewing both Chinese and English medical databases up to October 31, 2025.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 76 patients were included in the analysis, with a median age of 45 years (range: 9, 79), of which 65 (85.5%) were female. The median duration from the initiation of HCQ to the onset of symptoms was 5 days (range: 2, 122). In addition to the presence of nonfollicular, pinhead-sized pustules on erythematous and edematous skin, patients frequently exhibited fever (73.9%) and pruritus (59.4%). Laboratory evaluations typically revealed elevated peripheral blood neutrophil counts, erythrocyte sedimentation rate, and C-reactive protein levels in individuals with AGEP. Symptoms resolved in all patients with a median duration of 18.5 days (range: 5, 119) following the cessation of HCQ and appropriate management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>While HCQ is widely used in dermatology and rheumatology, AGEP remains a rare adverse event. Skin symptoms in patients taking HCQ should prompt consideration of this diagnosis. Prolonged latency of HCQ-induced AGEP is predominantly observed in female patients with rheumatic conditions. Timely recognition and management of AGEP are critical to guide appropriate drug management and ensure patient safety.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5392334","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydrogels for Local Treatment of Cutaneous Malignancies: Preclinical Progress and Translational Prospects","authors":"Ming-Xuan Ma,&nbsp;Shu-Li Gu,&nbsp;Jia-Ao Fang,&nbsp;Guang-Wen Yin","doi":"10.1155/dth/1039315","DOIUrl":"https://doi.org/10.1155/dth/1039315","url":null,"abstract":"<p>Cutaneous malignancies, including malignant melanoma and nonmelanoma skin cancers, are among the most common cancers worldwide and are currently treated with surgical excision as first-line therapy, while topical therapy also occupies an important position. Hydrogels are crosslinked hydrophilic polymer networks that can undergo in situ gelation on lesions or postoperative wounds, adhere to the skin and provide stimulus-responsive controlled release of drugs and have been developed as local delivery platforms, including microneedle-based systems, in preclinical treatment studies of cutaneous malignancies. This narrative review integrates preclinical studies from the past 5 years on hydrogel systems for local treatment of cutaneous malignancies from a dermatology-oriented translational perspective. Evidence is organised by therapeutic mechanism into light-mediated, immunomodulatory, antitumour–pro-repair and microneedle-delivered hydrogels. Light-mediated hydrogels combine photothermal or photodynamic components with tunable optical parameters to achieve near-infrared-triggered tumour ablation and, in some systems, simultaneous support of wound healing and remodelling. Immunomodulatory hydrogels construct local immune depots that reshape the tumour microenvironment, promote dendritic-cell maturation, enhance cytotoxic T-cell responses and regulate tumour-associated macrophage polarisation. Antitumour–pro-repair hydrogels coordinate local cytotoxic or metabolic effects with antioxidant, anti-inflammatory and barrier-restoring functions to sustain tumour suppression while supporting tissue repair, whereas microneedle-delivered hydrogels-coupled microneedle geometry and mechanics with in situ gelling or swelling to improve transdermal access, enable microenvironment sampling and facilitate outpatient application. Across these platforms, priorities include adhesion and resistance to exudate and friction, spatiotemporally controlled release, adequate mechanical strength and insertion performance, modular and couplable architectures, reproducible local dosing and triggering, biocompatibility and stability, integration with surgical and outpatient workflows, and validation within clinical frameworks focused on recurrence control, margin status and functional–cosmetic outcomes.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1039315","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the Research of Plasma in Dermatology by Bibliometric Approach","authors":"Jintong Wu,&nbsp;Zijie Tang,&nbsp;Su Wang,&nbsp;Yuxin Qiu,&nbsp;Chengxin Li,&nbsp;Rui Wang","doi":"10.1155/dth/1005755","DOIUrl":"https://doi.org/10.1155/dth/1005755","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Plasma applications can lead to effective therapy for numerous skin diseases. We aim to systematically review the available data and map the plasma medicine in dermatology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Publications relevant to plasma medicine in dermatology, published from 1996 to 2024, were retrieved from the Science Citation Index-Expanded of the Web of Science Core Collection. Visual maps were conducted regarding annual production, collaborating countries or institutions, productive authors, core journals, co-cited references, and keyword bursts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>460 articles were identified, and the number of publications has increased rapidly since 2008. Germany was the most influential country. Leibniz Institute for Plasma Science and Technology was the most productive institution. Weltmann, K. D. was the most prolific author. Wound healing, air plasma, dielectric barrier discharge, cold atmospheric plasma (CAP), antimicrobial, antifungal, argon plasma, plasma physical parameters, nitric oxide, and transdermal drug delivery were the top 10 clusters in the cocitation cluster analysis. Keyword burst analysis suggests that current research hotspots include CAP, nonthermal plasma, expression, and apoptosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study provides an overview of plasma sources and their applications in dermatology. Plasma mechanisms and effects are currently hot topics. Most plasma applications focus on wound healing, infectious skin diseases, immune-mediated skin diseases, and skin cancer. The parameter settings and treatment protocols of plasma for various skin diseases require further exploration. The present study maps the research landscape of CAP in dermatology and identifies directions for future investigation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1005755","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophil-to-Lymphocyte Ratio Dynamics and Progression-Free Survival in Advanced Cutaneous Squamous Cell Carcinoma Treated With Cemiplimab","authors":"Irina Ciobotariu,&nbsp;Lucia Di Nardo,&nbsp;Alessandro Di Stefani,&nbsp;Andrea Paradisi,&nbsp;Maria Mannino,&nbsp;Francesco Brunetti,&nbsp;Ketty Peris","doi":"10.1155/dth/8309058","DOIUrl":"https://doi.org/10.1155/dth/8309058","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Patients with locally advanced (la) and metastatic (m) cutaneous squamous cell carcinoma (CSCC) for which curative surgery or radiation is not available may benefit from treatment with anti–programmed cell death 1 (PD-1) monoclonal antibody cemiplimab. The predictive and prognostic role of hematological markers in such patients remains unclear.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Type of Study&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A real-life retrospective cohort study was conducted to evaluate the role of hematological inflammatory parameters as predictive and prognostic factors in patients with laCSCC and mCSCC who underwent first-line treatment with cemiplimab.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Lymphocyte–monocyte ratio (LMR), neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), albumin, creatinine, systemic immune–inflammation index (SII), and LDH were measured prior to cemiplimab therapy and subsequently at the first follow-up visit. To evaluate independent prognostic factors, the 12-month time-dependent performance was assessed using the incident/dynamic receiver operating characteristic (ROC) framework implemented with a nearest-neighbor estimator. Model performance metrics, including Harrell’s C-index and the time-dependent area under the curve (AUC), were quantified with 95% confidence intervals.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 43 CSCC patients including 37 (86.1%) with laCSCC and 6 (14.0%) with mCSCC were retrospectively enrolled. After a median of 33.1 weeks (8.4 months) of exposure to cemiplimab, ORR was 72% (31/43), including 41.9% (13/31) complete responses and 58.1% (18/31) partial responses; stable disease was observed in 9.7% (3/31). The median progression-free survival (PFS) was 6.4 months (IQR, 3.9–14.7 months). Overall, 7% of patients discontinued therapy due to adverse events (Grade 3 renal insufficiency and liver toxicity).&lt;/p&gt;\u0000 \u0000 &lt;p&gt;We identified a significant inverse association between NLR change from baseline to first on-treatment visit (ΔNLR) and PFS (Coeff = −0.25; 95% CI [jackknife] = −0.45–0.05, &lt;i&gt;p&lt;/i&gt; = 0.014), showing higher ΔNLR score in patients with shorter PFS. The ΔNLR was associated with a 36% higher chance of progression (HR = 1.36, 95% CI = 0.97–1.89, &lt;i&gt;p&lt;/i&gt; = 0.073), adjusted for age, systemic inflammatory index, and sex. Decision curve analysis showed a modest net benefit of the ΔNLR-based model across a broad range of threshold probabilities (approximately 7%–49%), without identification of a clinically optimal decision threshold.&lt;/","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8309058","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of a Spray Containing Retinol and Hydroxypinacolone Retinoate Encapsulated in Glycospheres, Salicylic Acid, Glycolic Acid, and Niacinamide Versus Vitamin A Acid 0.025% Lotion for the Treatment of Mild-to-Moderate Truncal Acne in Patients Treated With Doxycycline: A Randomized Controlled Trial","authors":"Salin Kiratikanon,&nbsp;Yuda Chongpison,&nbsp;Chanat Kumtornrut","doi":"10.1155/dth/6034446","DOIUrl":"https://doi.org/10.1155/dth/6034446","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Truncal acne affects life quality and poses unique treatment challenges. Novel formulations containing encapsulated retinol and hydroxypinacolone retinoate, the antimicrobial peptide BIOPEP-15 (BIOPEP-15), niacinamide, salicylic acid, and glycolic acid (RB + NSG) spray may offer benefits compared with traditional therapies when combined with oral antibiotics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To compare the efficacy, safety, and patient satisfaction of RB + NSG spray versus vitamin A acid (VAA) lotion in mild-to-moderate truncal acne treated alongside doxycycline.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This randomized, assessor-blinded trial involved 50 patients aged 18–45 with truncal acne. Patients were assigned to either RB + NSG spray twice daily or VAA 0.025% lotion at night. Both groups received oral doxycycline 100 mg twice daily. Lesion count reductions, skin surface lipid (SSL) changes, and quality of life (DLQI) were assessed. Patient satisfaction scores (PSSs) and side effects were evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty-eight patients completed the study. At 12 weeks, according to the noninferiority margin of 5, a total lesion count reduction in the RB + NSG spray group was noninferior compared to the VAA group. Both groups showed a significant decrease in the total lesion count reduction compared to the baseline (RB + NSG: -26.8, <i>p</i> &lt; 0.01, and VAA lotion: −18.1, <i>p</i> &lt; 0.01). DLQI improvements were greater with RB + NSG (−7.7 vs. −5.0; <i>p</i> = 0.002), and PSS favored RB + NSG (13.0 vs. 11.0; <i>p</i> = 0.012). Erythema was more common in the RB + NSG group (83.3%), but the dryness rate was lower (12.5% vs. 54.2%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The RB + NSG spray, used with doxycycline, is a comparably effective and better-tolerated alternative to VAA lotion for truncal acne, with respect to patients’ quality of life and satisfaction.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6034446","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Objective and Subjective Assessments of the Response of Photobiomodulation Therapy Against Alopecia Areata","authors":"Yi-Shan Liu,&nbsp;Chun-Ying Wu,&nbsp;Jeng-Fung Hung,&nbsp;Cheuk-Kwan Sun","doi":"10.1155/dth/2661014","DOIUrl":"https://doi.org/10.1155/dth/2661014","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Alopecia areata (AA), a T cell–mediated autoimmune inflammatory disease with an increasing incidence, not only has cosmetic and psychosocial impacts but is also associated with significant psychiatric comorbidities.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To investigate the therapeutic response of photobiomodulation therapy (PBMT) against AA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>This was a one-group pretest–posttest study in which PBMT (wavelength: 660 nm) was applied to the AA patients’ scalps twice weekly for 12 weeks. Objective and subjective treatment responses were assessed with the Severity of Alopecia Tool (SALT) and the Chinese version of the Dermatology Life Quality Index (DLQI), respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 30 adults initially recruited, five were excluded because of loss to follow-up. Finally, 25 individuals, including 11 males and 14 females, participated in the study. Comparison of the SALT scores on the four portions of the scalp (top, back, right side, and left side) demonstrated significant reductions following treatment (all <i>p</i> &lt; 0.001), suggesting notable improvements in hair regrowth. Cohen’s <i>d</i> values showed high therapeutic responses in all four scalp regions in the order of the back (1.56), left side (1.21), right side (1.10), and the top (0.82). The DLQI dropped significantly after treatment (<i>p</i> &lt; 0.001), indicating remarkable improvements in the quality of life after PBMT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>PBMT may be a promising noninvasive treatment option for patients with AA without systemic or local side effects.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2661014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Optimized Potent Barrier-Restoring Cream for Skin Repair: A Multicenter, Randomized, Double-Blind, Split-Face Controlled Clinical Study","authors":"Anqi Sheng,&nbsp;Miaoni Zhou,&nbsp;Wenting Hu,&nbsp;Ai’e Xu","doi":"10.1155/dth/3337739","DOIUrl":"https://doi.org/10.1155/dth/3337739","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>Severe sensitive skin significantly impairs patients’ quality of life, and moisturizer application has become a clinical imperative in its management. This study was designed to assess the skin barrier repair efficacy of an optimized, potent cream comprising <i>Portulaca oleracea</i> extract, <i>Prinsepia utilis</i> oil, <i>Citrus reticulata</i> peel extract, and <i>Polygonatum kingianum</i> extract.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A total of 103 eligible participants with sensitive skin were randomly assigned to apply the test cream (Cream A) on one cheek (left or right) and the control cream (Cream B) on the contralateral cheek, twice daily. Transepidermal water loss (TEWL), stratum corneum hydration (SCH), and erythema index (EI) were measured on both cheeks at baseline, as well as at 7, 14, and 28 days after product application. Clinical evaluations by two dermatologists and self-reports by participants were carried out at identical time points.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Both clinical evaluations and participant self-reports revealed that the application of either Cream A or Cream B significantly relieved discomfort symptoms, including erythema and burning sensations; Cream A demonstrated a faster alleviation of desquamation symptoms. Both creams significantly improved TEWL, SCH, and EI in participants with sensitive skin. Notably, compared to Cream B, Cream A achieved a significantly higher improvement rate in EI at Day 7 (<i>p</i> &lt; 0.05) and a greater improvement rate in TEWL at Day 28 (<i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Cream A exhibits a remarkable clinical value in rapidly alleviating erythema and desquamation, with notable advantages in restoring damaged skin barriers, serving as a novel long-term management strategy for sensitive skin.</p>\u0000 \u0000 <p><b>Trial Registration:</b> National Medical Research Registration and Filing Information System: MR-33-24-019764</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3337739","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical Complications of Tattooing: A Bicentric Retrospective Study","authors":"Letizia Tschudi,&nbsp;Kristine Heidemeyer,&nbsp;Isabel Kolm,&nbsp;Yannik Zobrist,&nbsp;Reinhard Dummer,&nbsp;Laurence Imhof","doi":"10.1155/dth/5557262","DOIUrl":"https://doi.org/10.1155/dth/5557262","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>Tattooing is very popular, but it can cause a variety of medical complications. Detailed knowledge about these complications and accurate diagnostic and therapeutic methods are needed. The aim of this study is to analyse cutaneous complications after tattooing, to describe diagnostic approaches and to elaborate therapeutic methods.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>We performed a retrospective systematic analysis of patients with tattoo complications who presented to the Departments of Dermatology at the University Hospitals Zurich and Bern between 2006 and 2020. A total of 58 patients were included and analysed regarding patient characteristics, tattoo characteristics, treatment of the tattoo complication and outcome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Frequent tattoo complications were adverse cutaneous inflammatory reactions, including hypersensitivity reactions (87.9%), in a few cases with systemic involvement, followed by development of neoplasms (6.9%; one melanoma, one superficial basal cell carcinoma, one squamous cell carcinoma and one viral acanthopapilloma with atypia) and cutaneous infections (5.2%). Different treatment methods were used depending on the suspected aetiology of the tattoo complication.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Cutaneous tattoo complications are polymorphous. A thorough work-up to rule out underlying systemic disease, malignancy, or infection is strongly recommended, especially in persistent, therapy-resistant cases. In patients with refractory inflammatory tattoo reactions, laser treatment may be a promising therapeutic option.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5557262","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}